Reviewing DAA Efficacy Managing Patient Treatment In Online Neighbourhoods
Reviewing DAA Efficacy Managing Patient Treatment In Online Neighbourhoods
REDEMPTION (Reviewing DAA Efficacy Managing Patient Treatment In Online Neighbourhoods) is
 observing and collating the treatment course, safety profile, and outcomes of patients around
 the world who are choosing to self import generic versions of the Direct Acting Antivirals
 Sofosbuvir, Ledipasvir and Daclatasvir from countries like China, India and Bangladesh.
The high prices of Hepatitis C Virus (HCV) Direct Acting Antiviral (DAA) medications in many
 countries have led patients to seek out less expensive generic alternatives.

 The efficacy and safety of these generic medications has not been formally demonstrated in
 clinical practice.

 The primary goal of REDEMPTION is to collate the clinical results of these generic
 medications.

 The secondary goal is to answer efficacy questions for which there is currently insufficient
 trial data available - for example Sofosbuvir+Daclatasvir appears to be an inexpensive pan
 genotypic solution to treat HCV globally but this is supported by a total n of less than
 1000, and in some common genotypes, such as HCV Genotype 2, by an n of only 52 making for a
 wide margin of error and a high degree of uncertainty.
Inclusion Criteria:

 Quantitative HCV RNA > 100

 Exclusion Criteria:

 Contraindications to DAA medications